Welcome to our dedicated page for GeneDx Holdings SEC filings (Ticker: WGS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The GeneDx Holdings Corp. (WGS) SEC filings page on Stock Titan provides access to the company’s public disclosures filed with the U.S. Securities and Exchange Commission. GeneDx is a Delaware‑incorporated company whose Class A common stock trades on The Nasdaq Stock Market under the symbol WGS, with related warrants trading under WGSWW, as noted in its current reports on Form 8‑K.
Investors and analysts can use this page to review current reports on Form 8‑K, which for GeneDx have included announcements of quarterly financial results, updated guidance, and significant corporate events such as board appointments and annual meeting outcomes. These filings offer detail on revenue composition, exome and genome test volumes, margin metrics, cash position, and shareholder voting results, as described in the company’s earnings‑related 8‑K filings.
Because GeneDx positions itself as a global leader in rare disease diagnosis and rare disease genomics, its periodic and current reports are a key source for understanding how its genomic testing business, GeneDx Infinity dataset, and related initiatives translate into financial performance and corporate governance decisions. Filings also disclose information about securities such as its warrants, including listing details and exercise price.
On Stock Titan, SEC documents are paired with AI‑powered summaries that help explain the contents of lengthy filings in accessible language. Users can quickly see the main points from GeneDx’s 8‑K disclosures, and, where applicable, locate information related to quarterly and annual reporting, capital structure, and significant events affecting WGS shareholders. Real‑time updates from EDGAR ensure that new GeneDx filings appear promptly, while AI‑generated highlights make it easier to navigate complex regulatory documents.
GeneDx Holdings Corp. filed a report stating that it issued a press release on January 12, 2026 outlining its expectations for preliminary, unaudited revenue for the fourth quarter and full year 2025. The update also covers exome and genome test result volumes, GAAP and adjusted gross margin for the same periods, and levels of cash, cash equivalents, marketable securities and restricted cash as of December 31, 2025.
The company additionally provided full year 2026 guidance and released an investor presentation prepared for the 44th Annual J.P. Morgan Healthcare Conference. These materials are furnished as exhibits and are not deemed filed for liability purposes under the securities laws or automatically incorporated into other regulatory documents.
GeneDx Holdings Corp. Chief Financial Officer insider transaction shows routine equity compensation activity. On December 16, 2025, the CFO exercised 7,197 restricted stock units (RSUs), receiving the same number of Class A common shares for no cash consideration. On the same date, multiple small blocks of Class A common stock were sold at weighted average prices between $138.93 and $150.75 per share.
According to the disclosure, these sales were made solely to cover tax withholding obligations arising from the RSU vesting under a “sell to cover” arrangement and were not discretionary trades by the executive. After these transactions, the CFO beneficially owned 8,731 shares of Class A common stock, as well as RSUs representing contingent rights to receive up to 113,504 shares and options to purchase up to 25,906 shares of Class A common stock, all vesting according to their existing terms.
GeneDx Holdings Corp.’s chief executive officer and director reported routine equity transactions involving Class A Common Stock on December 16, 2025. The filing shows 18,750 restricted stock units converting into the same number of shares at an exercise price of $0, increasing the executive’s directly held stock before related sales.
On the same date, the executive sold multiple small blocks of shares at weighted average prices reported between $138.93 and $150.75. According to the notes, these trades were made solely to cover tax withholding obligations tied to the RSU vesting and were not discretionary sales. After these transactions, the executive directly owned 14,237 shares of Class A Common Stock, plus RSUs representing up to 415,368 shares and options to purchase up to 107,610 shares, all vesting over time under their existing award terms.
GeneDx Holdings Corp. reported that its chief financial officer completed an equity award transaction involving Class A Common Stock on 12/09/2025. The filing shows 2,462 restricted stock units were converted into an equal number of shares at $0 exercise price, reflecting the vesting of previously granted RSUs.
To cover tax withholding triggered by this vesting, the officer sold 1,266 shares at $159.28 per share in a "sell to cover" transaction, described as non-discretionary. After these transactions, the officer beneficially owned 5,389 shares of Class A Common Stock, along with RSUs representing up to 120,701 additional shares and options for up to 25,906 shares, all subject to their vesting terms.
GeneDx Holdings Corp. (WGS) director reports insider share sales. A reporting person serving as a director filed a Form 4 for multiple sales of GeneDx Class A common stock on 11/24/2025. The trades were executed indirectly through investment entities Kariba LLC, Rugu2 LLC and VAAL Investment Partners Q9 LP, where the director has voting and investment power.
The sales occurred in several blocks at weighted average prices ranging from about $157.80 to $162.175 per share, with each block reported separately. After the reported transactions, the filing shows continued indirect beneficial ownership of GeneDx Class A shares by each of the three entities. The director disclaims beneficial ownership of these securities except to the extent of any pecuniary interest.
GeneDx Holdings (WGS) CEO and director reported an RSU settlement and related tax-withholding sales. On 10/29/2025, 3,874 shares of Class A Common Stock were acquired upon RSU vesting at $0 (code M), and 2,154 shares and 4 shares were sold at $136.54 and $136.75, respectively (code S), to cover tax obligations.
After these transactions, the reporting person held 3,436 Class A shares directly. In addition, they held RSUs representing up to 440,665 shares and options for up to 107,610 shares, which vest according to their terms. The RSU award vested 25% on April 29, 2023 and April 29, 2024, and 6.25% on each quarterly anniversary thereafter, with the last tranche scheduled for April 29, 2026.
GeneDx Holdings (WGS) CFO reported routine equity activity. On 10/29/2025, 753 restricted stock units settled into Class A shares at $0, and 388 shares were sold at $136.54 to cover tax withholding tied to the RSU vesting.
After these transactions, the reporting person beneficially owned 3,757 Class A shares. They also held RSUs representing up to 123,880 shares and options to purchase up to 25,906 shares, which vest according to their terms.
The RSU vesting schedule states 25% vested on April 29, 2023 and April 29, 2024, with an additional 6.25% vesting each quarterly anniversary thereafter, with the final tranche scheduled for April 29, 2026.
GeneDx Holdings (WGS) reported Q3 results showing strong top-line growth and improved profitability. Revenue rose to $116.7 million from $76.9 million, lifting gross profit to $84.5 million from $47.8 million. Loss from operations narrowed to $3.3 million from $7.8 million, and net loss was $7.6 million versus $8.3 million a year ago.
For the first nine months, revenue reached $306.6 million versus $209.8 million, with net loss improving to $3.4 million from $57.7 million. Cash and cash equivalents were $95.97 million, and marketable securities were $59.11 million as of September 30, 2025. The company closed the Fabric Genomics acquisition (aggregate purchase price $36.5 million), adding $12.8 million of goodwill and a $6.8 million contingent consideration liability; Fabric contributed $2.0 million of revenue in Q3.
Operating cash flow was $36.4 million year-to-date. Shares outstanding were 28,904,590 as of October 24, 2025; the company issued stock via its ATM in Q3 and year-to-date, raising $11.8 million and $25.6 million, respectively.
GeneDx Holdings Corp. furnished an 8-K announcing it issued a press release and will hold a conference call to discuss financial results for the quarter ended September 30, 2025.
The company attached its Press Release and an Earnings Presentation as Exhibits 99.1 and 99.2. The materials are furnished under Item 2.02 and are not deemed “filed” under Section 18 of the Exchange Act or incorporated by reference, except as specifically stated.
Keith A. Meister, a director and reported 10% owner, amended a Form 4 to correct previously misstated holdings in GeneDx Holdings Corp. (WGS). The amendment clarifies that investment funds advised by Corvex Management LP hold 2,473,781 shares of Class A common stock and that CMLS Holdings LLC holds 333,144 shares, for an aggregate indirect beneficial ownership of 2,806,925 shares. The filing states Mr. Meister may be deemed to indirectly own these shares through his control or board role but disclaims direct beneficial ownership except for any pecuniary interest. The amendment notes the corrected figures reflect a 1-for-33 reverse stock split effective
FAQ
What is the current stock price of GeneDx Holdings (WGS)?
What is the market cap of GeneDx Holdings (WGS)?
